Literature DB >> 12349828

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

Harvey Ben-Gary1, Robin L McKinney, Todd Rosengart, Martin L Lesser, Ronald G Crystal.   

Abstract

Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1(-) E3(-) Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) Ad(GV)CFTR.10, a vector carrying the normal human CFTR cDNA (3 x 10(7) to 2 x 10(10) particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) Ad(GV)VEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 x 10(8) to 4 x 10(10) pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 x 10(8) to 4 x 10(9.5) pu) of individuals with peripheral vascular disease (PVD); and 3) Ad(GV)CD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 x 10(7) to 7 x 10(9) pu) and airways (7 x 10(8) to 7 x 10(10) pu) of normal individuals and to liver metastasis (4 x 10(8) to 4 x 10(9) pu) of individuals with colon carcinoma. IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively. IL-6 responses were higher (up to 1100 pg/ml) following myocardial administration. Control individuals who had chest surgery and bronchoscopy, but no vector administration, had comparable IL-6 increases. Thus, both administration of Ad vectors of humans up to 10(10) pu and the procedures used to administer the vectors elicit systemic IL-6 responses. There was no correlation among peak IL-6 and peak anti-Ad antibodies. These observations indicate that the innate host responses following administration of Ad vectors to humans may result from the procedures used to administer the vector, and from the vector per se.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12349828     DOI: 10.1006/mthe.2002.0658

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  14 in total

1.  Genetic heterogeneity and efficiency of two different methods of adenovirus-mediated gene transfer in a rat liver transplantation model.

Authors:  Kensuke Adachi; Masayuki Fujino; Yusuke Kitazawa; Naoko Funeshima; Xiao-Kang Li
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 2.  Recognition of virus infection and innate host responses to viral gene therapy vectors.

Authors:  Dmitry M Shayakhmetov; Nelson C Di Paolo; Karen L Mossman
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

3.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates.

Authors:  Antonio Fontanellas; Sandra Hervás-Stubbs; Itsaso Mauleón; Juan Dubrot; Uxua Mancheño; María Collantes; Ana Sampedro; Carmen Unzu; Carlos Alfaro; Asis Palazón; Cristian Smerdou; Alberto Benito; Jesús Prieto; Iván Peñuelas; Ignacio Melero
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

5.  Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma.

Authors:  Gernot W Wolkersdörfer; Christian Thiede; Rainer Fischer; Gerhard Ehninger; Cornelie Haag
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

6.  A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.

Authors:  Daniel H Sterman; Adri Recio; Andrew R Haas; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Edmund Moon; Luana Pereira; Xinzhong Wang; Daniel F Heitjan; Leslie Litzky; Carl H June; Robert H Vonderheide; Richard G Carroll; Steven M Albelda
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

7.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.

Authors:  Pratik Singh; Duane Prasuhn; Robert M Yeh; Giuseppe Destito; Chris S Rae; Kent Osborn; M G Finn; Marianne Manchester
Journal:  J Control Release       Date:  2007-04-13       Impact factor: 9.776

8.  Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.

Authors:  Michael P Boquet; Piyanuch Wonganan; Joseph D Dekker; Maria A Croyle
Journal:  J Pharmacol Toxicol Methods       Date:  2008-08-03       Impact factor: 1.950

Review 9.  Viral nanoparticles as platforms for next-generation therapeutics and imaging devices.

Authors:  Nicole F Steinmetz
Journal:  Nanomedicine       Date:  2010-04-28       Impact factor: 5.307

10.  Virus infection recognition and early innate responses to non-enveloped viral vectors.

Authors:  Dmitry M Shayakhmetov
Journal:  Viruses       Date:  2010-01-19       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.